Codiak Biosciences EBIT

Codiak Biosciences (CDAK) currently reports a EBIT of $-53M as of September 2022. That compares with $-69M in the prior-year period — up 22.7% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Codiak Biosciences's EBIT history and peer comparisons.

Codiak Biosciences's EBIT increased from $-69M to $-53M — a 22.7% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Codiak Biosciences's EBIT of $-53M is lower than the Healthcare sector average of $23B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Codiak Biosciences reported $-53M in EBIT as of September 2022. That compares with $-69M in the prior-year period — up 22.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-53M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Codiak Biosciences, and consider following CDAK for alerts when major investors trade the stock.